619 West 54th Street, 8th Floor
Despite significant advances in treatment of primary tumors, metastatic cancer remains a leading cause of solid cancer mortality.1 HiberCell seeks to change that. As “the dormancy company,” we are the first company exclusively focused on therapeutically modulating the biology and mechanisms of tumor dormancy. Toward this goal we are developing first-in-class therapeutics that target dormant disseminated tumor cells (DTCs) from solid and liquid cancers. Our ultimate goal is to prevent or delay the recurrence of cancer.
3 jobs with HiberCell
This position will plan, coordinate and execute the activities surrounding external collaborations, investigator-initiated studies, clinical and scien
This position offers the opportunity to immediately impact a growing portfolio of related targeted therapy programs in a fast-paced, innovative scient
Perform in vivo studies to evaluate anti-cancer efficacy of test agents in tumor mouse models..